|02/19/14||MannKind Corporation to Present at Upcoming Conferences|
|VALENCIA, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences.
The RBC Capital Markets 2014 Global Healthcare Conference on February 25, 2014 at 11:30 AM (ET) at The New York Palace in New York, New York.
Cowen and Company 34th Annual Health Care Conference on March 3, 2014 at 3:30 PM (ET) at the Boston Marriott Copley i... |
|02/18/14||MannKind Corporation Reports 2013 Fourth Quarter and Full Year Financial Results|
|Conference Call to Begin Today at 5:00 PM ET
VALENCIA, Calif., Feb. 18, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2013.
For the fourth quarter of 2013, total operating expenses were $46.6 million, compared to $33.5 million for the fourth quarter of 2012, an increase of $13.1 million. Research and development (R&D) expenses were $29.0 million for the fourth quarter of 2013, compared... |
|02/04/14||MannKind Corporation to Hold 2013 Fourth Quarter and Full Year Financial Results Conference Call on February 18, 2014|
|VALENCIA, Calif., Feb. 4, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2013 fourth quarter and full year financial results on Tuesday, February 18, 2014 and its management will host a conference call to discuss the fourth quarter and full year financial results and other Company developments at 5:00 PM (Eastern Time) on February 18, 2014.
Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief Operating Of... |
|01/10/14||MannKind Announces Tentative Date of FDA Advisory Committee Review of AFREZZA|
|Endocrinologic and Metabolic Drugs Advisory Committee Meeting Tentatively Scheduled for April 1, 2014
VALENCIA, Calif., Jan. 10, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is tentatively scheduled on April 1, 2014 to review MannKind's New Drug Application (NDA) for AFREZZA® (insulin human [rDNA origin]) Inhalation Powder. The date and details of the meet... |
|01/08/14||MannKind Corporation to Present at the J.P. Morgan 2014 Healthcare Conference|
|VALENCIA, Calif., Jan. 8, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the J.P. Morgan 2014 Healthcare Conference on Wednesday, January 15, 2014 at 7:30 AM (PST) at Westin St. Francis Hotel in San Francisco, California.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at... |